Myriad Genetic Shares Jump 8% On News Recommendations For Tests
26 3월 2009 - 1:43AM
Dow Jones News
Myriad Genetic (MYGN) shares jumped 8% to $87.91 on Wednesday,
following news that the American College of Obstetricians and
Gynecologists is recommending doctors routinely evaluate whether a
patient is at risk of carrying a genetic mutation of the BRCA1 or
BRCA2 gene.
As carriers of the mutation generally have a markedly higher
risk of developing breast or ovarian cancer, doctors may choose to
take preventative measures, such as removal of the ovaries and
fallopian tubes.
Myriad markets a genetic screening test for the BRCA1 and BRCA2
mutations called BRACAnalysis.